Stemline seeks $50mn IPO to advance cancer therapeutics
This article was originally published in Scrip
Executive Summary
New York-based Stemline Therapeutics filed documents with the US Securities and Exchange Commission on 2 April to support a $50 million initial public offering at some unnamed date in the future.